Cover Image
市場調查報告書

癌症免疫療法的全球市場 - 至2021年的預測:單株抗體,癌症疫苗,免疫查核點抑制劑,免疫刺激劑

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 370999
出版日期 內容資訊 英文 142 Pages
訂單完成後即時交付
價格
Back to Top
癌症免疫療法的全球市場 - 至2021年的預測:單株抗體,癌症疫苗,免疫查核點抑制劑,免疫刺激劑 Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
出版日期: 2016年09月15日 內容資訊: 英文 142 Pages
簡介

全球癌症免疫療法市場,預計從2016年的619億7000萬美元,到2021年擴大到1,193億9000萬美元。市場預計2016年∼2021年以14.0%的年複合成長率成長。

本報告提供全球癌症免疫療法市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 癌症免疫療法市場的有利機會

第5章 癌症免疫療法的全球市場:概要

  • 簡介
    • 推動因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球癌症免疫療法資金概要

第6章 癌症免疫療法的全球市場:產業趨勢

  • 癌症免疫療法市場全球趨勢
  • 全球癌症免疫療法市場價格變動
  • 中小企業的配合,帶給癌症免疫療法市場長期性的影響
  • 製藥產業的魅力
  • 對於不同的種類的癌症的癌症免疫療法的變動熱圖

第7章 癌症免疫療法的全球市場:各類型產品

  • 簡介
  • 單株抗體
  • 疫苗
  • 免疫查核點抑制劑
  • 細胞療法
  • 免疫刺激劑

第8章 癌症免疫療法的全球市場:各用途

  • 簡介
  • 肺癌
  • 乳癌
  • 多發性骨髓瘤
  • 大腸癌
  • 頭頸椎癌症
  • 前列腺癌
  • 黑色素瘤
  • 其他

第9章 癌症免疫療法的全球市場:各終端用戶

  • 簡介
  • 醫院
  • 門診病人診療所,其他

第10章 癌症免疫療法的全球市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第11章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形與趨勢

第12章 企業簡介

  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND COMPANY
  • JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON)
  • MERCK
  • NOVARTIS
  • PFIZER
  • F. HOFFMANN-LA ROCHE LTD

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 4576

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market.

The global cancer immunotherapy market has been segmented on the basis of type, application, end user, and region. The monoclonal antibodies segment is expected to register the highest growth rate in the cancer immunotherapy market, by type, during the forecast period. Factors such as high success rate and less recovery time are contributing to the high growth in this segment.

Based on application, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others (renal cell carcinoma, cervical, gastric, and lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2016 to 2021, primarily due to the rising prevalence of this type of cancer.

Based on end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of drugs in hospitals.

Geographically, the cancer immunotherapy market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of North America can be attributed to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity.

Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output, in order to remain successful in the cancer immunotherapy market.

The major players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

OBJECTIVES OF THE STUDY:

  • To define, describe, and forecast the global cancer immunotherapy market on the basis of type, application, end user, and region
  • To provide detailed information regarding the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the global cancer immunotherapy market
  • To strategically analyze the markets with respect to their individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their market shares and core competencies
  • To analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and R&D activities in the global cancer immunotherapy market

Target Audience for this Report:

  • Drug Manufacturers and Suppliers
  • Academic Research Institutes
  • Hospitals and Clinics
  • Research and Development (R&D) Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers and Universities

Scope of the Report:

In this report, the cancer immunotherapy market has been segmented into the following segments and subsegments:

Cancer Immunotherapy Market, by Type

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators

Cancer Immunotherapy Market, by Application

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Cancer Immunotherapy Market, by End User

  • Hospitals
  • Clinics & Others

Cancer Immunotherapy Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • RoE
  • APAC
    • India
    • China
    • Japan
    • RoAPAC
  • Rest of the World (RoW)
    • South America, Central America, and the Caribbean
    • Oceania
    • Africa

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKETS COVERED
    • 1.3.1. PERIODIZATION
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
    • 2.1.2. KEY DATA FROM PRIMARY SOURCES
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
    • 3.3.1. FUTURE OF CANCER IMMUNOTHERAPEUTICS

4. PREMIUM INSIGHTS

  • 4.1. LUCRATIVE OPPORTUNITIES IN THE CANCER IMMUNOTHERAPY MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. DRIVERS
    • 5.2.1. RISE IN INCIDENCE OF CANCER
    • 5.2.2. INCREASE IN ADOPTION OF IMMUNOTHERAPY OVER OTHER TREATMENT OPTIONS
    • 5.2.3. DEVELOPMENT OF BIOINFORMATIC TOOLS ENHANCING DRUG DEVELOPMENT PROCESS
  • 5.3. RESTRAINTS
    • 5.3.1. HIGH COST OF TREATMENT
  • 5.4. OPPORTUNITIES
    • 5.4.1. INCREASE IN CLINICAL TRIALS AGAINST SEVERAL TYPES OF CANCERS IN IMMUNOTHERAPY
    • 5.4.2. HIGH GROWTH PROSPECTS IN DEVELOPING COUNTRIES
  • 5.5. CHALLENGES
    • 5.5.1. AVAILABILITY OF LIMITED FUNDS TO INITIATE CLINICAL TRIALS
    • 5.5.2. COMPLEXITY OF CANCER LIMITING THE IMMUNE RESPONSE
  • 5.6. OVERVIEW OF GLOBAL CANCER IMMUNOTHERAPY FUNDING
  • 5.7. CONVENTIONAL CANCER THERAPY VERSUS CANCER IMMUNOTHERAPY

6. INDUSTRY TRENDS

  • 6.1. GLOBAL TRENDS IN THE CANCER IMMUNOTHERAPY MARKET
    • 6.1.1. FDA APPROVALS FOR OPDIVO (NIOLUMAB) AND KEYTRUDA (PEMBROLIZUMAB) IN THE U.S. PRESENT ATTRACTIVE OPPORTUNITIES
    • 6.1.2. COMBINATION IMMUNOTHERAPY A POTENTIAL WAY TO TREAT MELANOMA
    • 6.1.3. U.S. CANCER IMMUNOTHERAPY RESEARCH COMMUNITY BUILDS HOPE TO COMBAT CANCER BY 2020
    • 6.1.4. U.K. SCIENTISTS PROJECT A CHANGE IN THE MEANS OF TREATMENT FOR CANCER WITH QUALITY THERAPIES
    • 6.1.5. WORLD IS MOVING TOWARD PERSONALIZED IMMUNOTHERAPY
    • 6.1.6. A COMBINATION OF MODERN IMMUNOTHERAPY AND TRADITIONAL CHINESE MEDICINES CONTINUES TO INCREASE THE SURVIVAL RATE OF PATIENTS IN CHINA
  • 6.2. PRICING VARIATIONS IN THE GLOBAL CANCER IMMUNOTHERAPY MARKET
  • 6.3. SMALL PLAYERS COLLABORATING TO MAKE LONG-TERM IMPACT IN THE CANCER IMMUNOTHERAPY MARKET
  • 6.4. ATTRACTIONS FOR THE PHARMACEUTICAL INDUSTRY
  • 6.5. HEAT MAP FOR VARIATIONS IN CANCER IMMUNOTHERAPY FOR DIFFERENT TYPES OF CANCERS
    • 6.5.1. BREAST CANCER
    • 6.5.2. LUNG CANCER
    • 6.5.3. MULTIPLE MYELOMA
    • 6.5.4. LYMPHOMA

7. CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE

  • 7.1. INTRODUCTION
  • 7.2. MONOCLONAL ANTIBODIES
    • 7.2.1. NAKED MONOCLONAL ANTIBODIES
    • 7.2.2. CONJUGATED MONOCLONAL ANTIBODIES
    • 7.2.3. BISPECIFIC MONOCLONAL ANTIBODIES
  • 7.3. VACCINES
    • 7.3.1. PROPHYLACTIC VACCINES
    • 7.3.2. THERAPEUTIC VACCINES
  • 7.4. CHECKPOINT INHIBITORS
    • 7.4.1. CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4(CTLA-4)
    • 7.4.2. PROGRAMMED DEATH 1(PD-1) & PROGRAMMED DEATH LIGAND 1(PD-L1)
  • 7.5. CELL THERAPIES
    • 7.5.1. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
    • 7.5.2. DENDRITIC CELLS
  • 7.6. IMMUNOMODULATORS
    • 7.6.1. GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF)
    • 7.6.2. INTERFERONS (IFN)
    • 7.6.3. INTERLEUKINS (IL)
    • 7.6.4. ONCOLYTIC VIRUS
      • 7.6.4.1. Immunotherapy
      • 7.6.4.2. Immunity as an obstacle
      • 7.6.4.3. Immunity as an ally
      • 7.6.4.4. Approved Products & Clinical Trails

8. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. LUNG CANCER
  • 8.3. BREAST CANCER
  • 8.4. MULTIPLE MYELOMA
  • 8.5. COLORECTAL CANCER
  • 8.6. HEAD & NECK CANCER
  • 8.7. PROSTATE CANCER
  • 8.8. MELANOMA
  • 8.9. OTHER CANCER TYPES

9. CANCER IMMUNOTHERAPY MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS
  • 9.3. CLINICS & OTHERS

10. CANCER IMMUNOTHERAPY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
  • 10.3. EUROPE
  • 10.4. ASIA-PACIFIC
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. APPROVALS
    • 11.3.2. AGREEMENTS, PARTNERSHIPS & COLLABORATIONS
    • 11.3.3. ACQUISITIONS
    • 11.3.4. EXPANSIONS
    • 11.3.5. OTHER DEVELOPMENTS

12. COMPANY PROFILE (Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*

  • 12.1. AMGEN INC.
  • 12.2. ASTRAZENECA
  • 12.3. BAYER AG
  • 12.4. BRISTOL-MYERS SQUIBB
  • 12.5. ELI LILLY AND COMPANY
  • 12.6. JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON)
  • 12.7. MERCK
  • 12.8. NOVARTIS
  • 12.9. PFIZER
  • 12.10. F. HOFFMANN-LA ROCHE LTD 130.

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: OVERVIEW OF FUNDING PATTERNS FOR DIFFERENT TYPES OF CANCER BY NIH, U.S., 2012-2017 (USD MILLION)
  • TABLE 2: OVERVIEW OF KEY FUNDING IN CANCER IMMUNOTHERAPY MARKET, 2016
  • TABLE 3: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 4: CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBTYPE, 2014-2021 (USD MILLION)
  • TABLE 5: CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: NAKED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: CONJUGATED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: BISPECIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: VACCINES MARKET SIZE, BY SUBTYPE, 2016-2021 (USD MILLION)
  • TABLE 10: VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: PROPHYLACTIC VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: CHECKPOINT INHIBITORS MARKET SIZE, BY SUBTYPE, 2014-2021 (USD MILLION)
  • TABLE 14: CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: PD-1 & PD-L1 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: IMMUNOMODULATORS MARKET SIZE, BY SUBTYPE, 2014-2021 (USD MILLION)
  • TABLE 18: IMMUNOMODULATORS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: INTERFERONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: INTERLEUKINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: CANCER IMMUNOTHERAPY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 23: LUNG CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: BREAST CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: COLORECTAL CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: HEAD & NECK CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: PROSTATE CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: MELANOMA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: OTHER TYPES OF CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 32: HOSPITALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: CLINICS & OTHERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 34: CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2016-2021(USD MILLION)
  • TABLE 36: EUROPE: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 37: ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 38: ROW: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 39: APPROVALS, 2013-2016
  • TABLE 40: AGREEMENTS, PARTNERSHIPS & COLLABORATIONS, 2013-2016
  • TABLE 41: ACQUISITIONS, 2013-2016
  • TABLE 42: EXPANSIONS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: CLASSIFICATION OF CANCER IMMUNOTHERAPY
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: THE MONOCLONAL ANTIBODY SEGMENT IS EXPECTED TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET DURING THE FORECAST PERIOD
  • FIGURE 8: THE LUNG CANCER SEGMENT LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015
  • FIGURE 9: HOSPITALS ARE MAJOR END USERS OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET
  • FIGURE 10: NORTH AMERICA LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015
  • FIGURE 11: GLOBAL CANCER IMMUNOTHERAPY MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
  • FIGURE 12: LUNG CANCER APPLICATION DOMINATED THE GLOBAL CANCER IMMUNOTHERAPY MARKET, 2016
  • FIGURE 13: ROW TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: LUNG CANCER TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD IN THE CANCER IMMUNOTHERAPY MARKET
  • FIGURE 15: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: PROJECTED INCREASE IN CANCER CASES, EXCLUDING NON-MELANOMA SKIN CANCER, 2012 VS. 2020
  • FIGURE 17: PRICING TREND OF IMBRUVICA ACROSS THE MAJOR PHARMACEUTICAL MARKET IN 2016
  • FIGURE 18: HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR BREAST CANCER
  • FIGURE 19: ANNUAL COST OF BREAST CANCER IMMUNOTHERAPY, 2016
  • FIGURE 20: HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LUNG CANCER
  • FIGURE 21: ANNUAL COST OF LUNG CANCER IMMUNOTHERAPY, 2016
  • FIGURE 22: HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR MULTIPLE MYELOMA
  • FIGURE 23: ANNUAL COST OF MULTIPLE MYELOMA IMMUNOTHERAPY, 2016
  • FIGURE 24: HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LYMPHOMA
  • FIGURE 25: ANNUAL COST OF LYMPHOMA IMMUNOTHERAPY, 2016
  • FIGURE 26: CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE
  • FIGURE 27: MONOCLONAL ANTIBODIES SEGMENT IS ESTIMATED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN 2016
  • FIGURE 28: NAKED MONOCLONAL ANTIBODIES ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 29: NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER MONOCLONAL ANTIBODIES MARKET IN 2016
  • FIGURE 30: VACCINES MARKET, BY SUBTYPE, 2016-2021 (USD MILLION)
  • FIGURE 31: NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING IN THE VACCINES MARKET
  • FIGURE 32: PROGRAMMED DEATH 1(PD-1) IS PROJECTED TO BE THE FASTER-GROWING SEGMENT OF THE CHECKPOINT INHIBITORS MARKET
  • FIGURE 33: ROW IS PROJECTED TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE CHECKPOINT INHIBITORS MARKET
  • FIGURE 34: GM-CSF & G-CSF SUB-SEGMENT IS PROJECTED TO DOMINATE THE IMMUNOMODULATORS SEGMENT THROUGH 2021
  • FIGURE 35: NORTH AMERICA IS PROJECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE IMMUNOMODULATORS MARKET THROUGH 2021
  • FIGURE 36: CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
  • FIGURE 37: LUNG CANCER SEGMENT IS ESTIMATED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN 2016
  • FIGURE 38: NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE LUNG CANCER IMMUNOTHERAPY MARKET IN 2016
  • FIGURE 39: NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER IN 2016
  • FIGURE 40: NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR MULTIPLE MYELOMA IN 2016
  • FIGURE 41: NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER IN 2016
  • FIGURE 42: NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER IN 2016
  • FIGURE 43: NORTH AMERICA IS ESTIMATED TO DOMINATE THE IMMUNOTHERAPY MARKET FOR PROSTATE CANCER IN 2016
  • FIGURE 44: NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE CANCER IMMUNOTHERAPY MARKET FOR MELANOMA DURING THE FORECAST PERIOD
  • FIGURE 45: ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE IMMUNOTHERAPY MARKET FOR OTHER CANCER TYPES, 2016-2021
  • FIGURE 46: CANCER IMMUNOTHERAPY MARKET, BY END USER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 47: HOSPITALS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)
  • FIGURE 48: CLINICS & OTHERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)
  • FIGURE 49: GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION FROM 2016 TO 2021
  • FIGURE 50: ROW REGION IS PROJECTED TO GROW AT THE HIGHEST RATE FROM 2016 TO 2021
  • FIGURE 51: NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016
  • FIGURE 52: THE CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO BE THE FASTEST-GROWING THROUGH 2021
  • FIGURE 53: MONOCLONAL ANTIBODIES SEGMENT IS PROJECTED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN EUROPE THROUGH 2021
  • FIGURE 54: ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016
  • FIGURE 55: CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN THE ROW REGION THROUGH 2021
  • FIGURE 56: COMPANIES ADOPTED APPROVALS AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS
  • FIGURE 57: GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2015
  • FIGURE 58: APPROVALS: THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2015
  • FIGURE 59: AMGEN INC.: COMPANY SNAPSHOT
  • FIGURE 60: ASTRAZENECA: COMPANY SNAPSHOT
  • FIGURE 61: BAYER AG: COMPANY SNAPSHOT
  • FIGURE 62: BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • FIGURE 63: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 64: JANSSEN GLOBAL SERVICES, LLC: COMPANY SNAPSHOT
  • FIGURE 65: MERCK: COMPANY SNAPSHOT
  • FIGURE 66: NOVARTIS: COMPANY SNAPSHOT
  • FIGURE 67: PFIZER: COMPANY SNAPSHOT
  • FIGURE 68: F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
Back to Top